Trial Profile
Sdai eduction with Certolizumab Pegol (Czp) in Patients with Rheumatoid Arthritis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Jul 2018
Price :
$35
*
At a glance
- Drugs Certolizumab pegol (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- 15 Jul 2018 New trial record
- 16 Jun 2018 Results assessing Sdai eduction with Certolizumab Pegol, presented at the 19th Annual Congress of the European League Against Rheumatism